––––––––––––––––––––
Subscribe to the Legal News!
https://test.legalnews.com/Home/Subscription
Full access to public notices, articles, columns, archives, statistics, calendar and more
Day Pass Only $4.95!
One-County $80/year
Three-County & Full Pass also available
- Posted April 28, 2010
- Tweet This | Share on Facebook
Nation - Supreme Court Court says Vioxx lawsuit can proceed Investors lost tens of billions of dollars in value
By Jesse J. Holland
Associated Press Writer
WASHINGTON (AP) -- The Supreme Court said Tuesday that investors who lost millions when Merck & Co. pulled its blockbuster pain drug Vioxx off the market can go ahead with a lawsuit against the pharmaceutical giant.
The high court agreed with a federal appeals court's decision to allow a class-action securities lawsuit. The suit was over whether the drugmaker provided adequate information about the risks of its former blockbuster painkiller Vioxx before it was pulled from the market.
Investors lost tens of billions of dollars in shareholder value overnight after Merck withdrew Vioxx.
The Whitehouse Station, N.J.-based company pulled the drug on Sept. 30, 2004, because it doubled the risks of heart attack, stroke and death.
Investors have two years to sue a company accused of defrauding investors. Merck argued that the two-year clock began when the first hint of Vioxx trouble was made public in September 2001. Investors argued that the two-year time limit should not have been started in 2001.
Justice Stephen Breyer, writing a unanimous judgment for the court, agreed with the investors. "The plaintiff's suit is timely," he said.
After it pulled Vioxx from the market, Merck was sued by shareholders, patients and survivors claiming Vioxx caused heart attacks and strokes, and from insurance plans seeking reimbursement for their costs for covering Vioxx prescriptions.
Merck says the investors should have known from public information that there could be problems with the drug because the regulatory Food and Drug Administration had issued warnings to Merck about Vioxx risks late in September 2001.
A federal judge agreed and dismissed the November 2003 lawsuit, ruling it was filed after the two-year statute of limitations expired.
But the Philadelphia-based 3rd U.S. Circuit Court of Appeals reversed that decision, allowing the many shareholder lawsuits, now consolidated in federal court, to proceed.
The appeals court said the investors could not have known more than two years ahead of time of the possible wrongdoing.
Merck has not proved otherwise, said Justice Antonin Scalia in a separate opinion.
"Merck has not shown that respondents actually discovered (possible wrongdoing) more than two years before bringing suit," said Scalia, who was joined in his separate opinion by Justice Clarence Thomas.
The case is Merck v. Reynolds, 08-905.
Published: Wed, Apr 28, 2010
headlines Detroit
headlines National
- Lucy Lang, NY inspector general, has always wanted rules evenly applied
- ACLU and BigLaw firm use ‘Orange is the New Black’ in hashtag effort to promote NY jail reform
- 2024 Year in Review: Integrated legal AI and more effective case management
- How to ensure your legal team is well-prepared for the shifting privacy landscape
- Judge denies bid by former Duane Morris partner to stop his wife’s funeral
- Attorney discipline records short of disbarment would be expunged after 8 years under state bar plan